AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17109680 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon (Peg‐IFN) alpha‐2b 1.5 microg/kg/week plus ribavirin 800 mg/day for 48 weeks (in patients with low viraemia)
Number of subjects: 203
Study 17109680 — intervention group
Group type: COMPARATOR
Intervention: Pegylated interferon (Peg‐IFN) alpha‐2b 0.75 microg/kg/week plus ribavirin 800 mg/day for 48 weeks (in patients with low viraemia)
Number of subjects: 203
Study 17109680 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon (Peg‐IFN) alpha‐2b 1.5 microg/kg/week plus ribavirin 800 mg/day for 48 weeks (in patients with high viraemia)
Number of subjects: 203
Study 17109680 — intervention group
Group type: COMPARATOR
Intervention: Pegylated interferon (Peg‐IFN) alpha‐2b 0.75 microg/kg/week plus ribavirin 800 mg/day for 48 weeks (in patients with high viraemia)
Number of subjects: 203
Study 17109680 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon (Peg‐IFN) alpha‐2b (both doses) plus ribavirin 800 mg/day for 48 weeks (in patients with genotypes 2 and 3)
Number of subjects: 203
Study 14720526 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 44
Study 14720526 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents
Number of subjects: 44
Study 11722967 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy prenatal supplementation
Number of subjects: 472
Study 11722967 — intervention group
Group type: COMPARATOR
Intervention: Control group (no high-energy prenatal supplementation)
Number of subjects: 472
Study 9394976 — intervention group
Group type: EXPERIMENTAL
Intervention: Inducible nitric oxide synthase (iNOS) expression in allergic contact dermatitis (n=8)
Number of subjects: 22
Study 9394976 — intervention group
Group type: EXPERIMENTAL
Intervention: Inducible nitric oxide synthase (iNOS) expression in irritant contact dermatitis (n=8)
Number of subjects: 22
Study 9394976 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (n=6)
Number of subjects: 22
Study 7967105 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd-DTPA enhanced MRI
Number of subjects: 25
Study 7967105 — intervention group
Group type: COMPARATOR
Intervention: Contrast CT
Number of subjects: 25
Study 3652000 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone 10 mg/m2 single intravenous dose
Number of subjects: 156
Study 3652000 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone in five consecutive daily fractions of 2 mg/m2
Number of subjects: 156
Study 3652000 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinblastine continuous intravenous infusion of 1.2 mg/m2 daily for 5 days
Number of subjects: 156
Study 3652000 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone and vinblastine combination
Number of subjects: 156
Study 31049136 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate supplementation (NO session)
Number of subjects: 14
Study 31049136 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation (PL session)
Number of subjects: 14
Study 26410977 — intervention group
Group type: EXPERIMENTAL
Intervention: Practical demonstration group
Number of subjects: 117
Study 26410977 — intervention group
Group type: COMPARATOR
Intervention: Written instruction group
Number of subjects: 117
Study 26410977 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 117
Study 23252809 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol group
Number of subjects: 87
Study 23252809 — intervention group
Group type: COMPARATOR
Intervention: Sober group
Number of subjects: 87
Study 23252809 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 87
Study 21498279 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-osmolar contrast medium (LOCM)
Number of subjects: 92
Study 21498279 — intervention group
Group type: COMPARATOR
Intervention: Iso-osmolar contrast medium (IOCM)
Number of subjects: 92
Study 21498279 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LOCM and IOCM
Number of subjects: 92
Study 19386449 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration plus resistance (VR)
Number of subjects: 55
Study 19386449 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance only (RG)
Number of subjects: 55
Study 19386449 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising control (CG)
Number of subjects: 55
Study 16776732 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitions photochromic spectacle lenses
Number of subjects: 50
Study 16776732 — intervention group
Group type: COMPARATOR
Intervention: Clear spectacle lenses
Number of subjects: 50
Study 12631557 — intervention group
Group type: EXPERIMENTAL
Intervention: Asimadoline 0.15 mg
Number of subjects: 91
Study 12631557 — intervention group
Group type: EXPERIMENTAL
Intervention: Asimadoline 0.5 mg
Number of subjects: 91
Study 12631557 — intervention group
Group type: EXPERIMENTAL
Intervention: Asimadoline 1.5 mg
Number of subjects: 91
Study 12631557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 11111815 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface treated catheters (Spi‐Argent, Spire Corporation, Bedford, MA, U.S.A.; n = 78 total; n = 32 acute catheters, n = 46 long‐term catheters)
Number of subjects: 135
Study 11111815 — intervention group
Group type: COMPARATOR
Intervention: Untreated catheters (n = 92 total; n = 40 acute catheters, n = 52 long‐term catheters)
Number of subjects: 135
Study 11111815 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface treated catheters
Number of subjects: 135
Study 9171807 — intervention group
Group type: EXPERIMENTAL
Intervention: Node-link mapping enhanced counseling
Number of subjects: 0
Study 9171807 — intervention group
Group type: COMPARATOR
Intervention: Standard counseling
Number of subjects: 0
Study 8438618 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-3 x 10(9) c.f.u. of lyophilized vaccine, administered in three oral inoculations
Number of subjects: 143
Study 8438618 — intervention group
Group type: EXPERIMENTAL
Intervention: Single application of the total dose for primary immunization or booster
Number of subjects: 143
Study 3503114 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 1% twice daily
Number of subjects: 0
Study 3503114 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5% twice daily
Number of subjects: 0
Study 3503114 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 0
Study 28882061 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (N=23)
Number of subjects: 34
Study 28882061 — intervention group
Group type: COMPARATOR
Intervention: Control group (N=11)
Number of subjects: 34
Study 27155917 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol-rich diet
Number of subjects: 72
Study 27155917 — intervention group
Group type: COMPARATOR
Intervention: In vitro colon model
Number of subjects: 72
Study 27155917 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro hepatic models
Number of subjects: 72
Study 24357403 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (Xience V)
Number of subjects: 215
Study 24357403 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent (Multi-Link Vision)
Number of subjects: 215
Study 22539077 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed dye laser (PDL, 595 nm) treatment
Number of subjects: 26
Study 22539077 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated keloids)
Number of subjects: 26
Study 20812009 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 15586
Study 20812009 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 15586
Study 18550554 — intervention group
Group type: EXPERIMENTAL
Intervention: BP stent
Number of subjects: 605
Study 18550554 — intervention group
Group type: COMPARATOR
Intervention: PP stent
Number of subjects: 605
Study 18550554 — intervention group
Group type: EXPERIMENTAL
Intervention: PF stent
Number of subjects: 605
Study 16026014 — intervention group
Group type: COMPARATOR
Intervention: Low intensity training (60 minutes per week for two weekly training sessions)
Number of subjects: 20
Study 16026014 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle intensity training (2 1/2 hours of training per week for 5 weekly training sessions)
Number of subjects: 20
Study 16026014 — intervention group
Group type: COMPARATOR
Intervention: Low intensity training
Number of subjects: 20
Study 16026014 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle intensity training
Number of subjects: 20
Study 12053882 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron before anaesthesia
Number of subjects: 148
Study 12053882 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron at the end of anaesthesia
Number of subjects: 148
Study 12053882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 11922260 — intervention group
Group type: EXPERIMENTAL
Intervention: Method B (silicone impression material in a custom acrylic tray)
Number of subjects: 6
Study 11922260 — intervention group
Group type: COMPARATOR
Intervention: Method A (transparent vacuum stent material)
Number of subjects: 6
Study 9833299 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent ondansetron (24 mg i.v. q 12 h/day)
Number of subjects: 66
Study 9833299 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion ondansetron (8 mg i.v. loading dose followed by a continuous infusion of 2 mg/h per day)
Number of subjects: 66
Study 8074600 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal vaccine
Number of subjects: 92
Study 2690549 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 15
Study 2690549 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 15
Study 30415646 — intervention group
Group type: EXPERIMENTAL
Intervention: Written prayer technique
Number of subjects: 90
Study 30415646 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal daily schedules writing)
Number of subjects: 90
Study 28758542 — intervention group
Group type: EXPERIMENTAL
Intervention: Camp Group (CG) - six-week day-camp weight-loss programme followed by a family-based supportive programme with four meetings during the succeeding 46 weeks
Number of subjects: 115
Study 28758542 — intervention group
Group type: EXPERIMENTAL
Intervention: Camp Group (CG)
Number of subjects: 115
Study 28758542 — intervention group
Group type: COMPARATOR
Intervention: Standard Group (SG) - weekly two-hour exercise session for six weeks
Number of subjects: 115
Study 25938778 — intervention group
Group type: EXPERIMENTAL
Intervention: Tangshen Formula (TSF) for 24 weeks
Number of subjects: 180
Study 25938778 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 24 weeks
Number of subjects: 180
Study 25938778 — intervention group
Group type: EXPERIMENTAL
Intervention: Tangshen Formula (TSF)
Number of subjects: 180
Study 25938778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 23055001 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate treatment in a 2-week, double-blind, placebo-controlled trial
Number of subjects: 0
Study 23055001 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate treatment
Number of subjects: 0
Study 23055001 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study 22050863 — intervention group
Group type: EXPERIMENTAL
Intervention: Training of general practitioners (GPs) in identifying palliative patients and delivering structured proactive palliative care.
Number of subjects: 0
Study 22050863 — intervention group
Group type: EXPERIMENTAL
Intervention: Consulting an expert in palliative care regarding each palliative patient's tailored care plan.
Number of subjects: 0
Study 22050863 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 18649556 — intervention group
Group type: EXPERIMENTAL
Intervention: Microetching prior to acid-etching
Number of subjects: 64
Study 18649556 — intervention group
Group type: COMPARATOR
Intervention: Conventional acid-etching
Number of subjects: 64
Study 16838235 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% acyclovir cream (topical iontophoretic application)
Number of subjects: 200
Study 12946072 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound for 10 minutes
Number of subjects: 30
Study 12946072 — intervention group
Group type: EXPERIMENTAL
Intervention: Masserann trephining bur (4‐mm‐deep gutter cut)
Number of subjects: 30
Study 12946072 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 10874684 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuronavigation
Number of subjects: 52
Study 10874684 — intervention group
Group type: COMPARATOR
Intervention: Conventional operations
Number of subjects: 52
Study 9106687 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative hyperthermia combined with chemotherapy and irradiation (HCR therapy) followed by surgery
Number of subjects: 88
Study 9106687 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (control group)
Number of subjects: 88
Study 9106687 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative hyperthermia combined with chemotherapy and irradiation (HCR therapy) plus surgery
Number of subjects: 88
Study 8195847 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodimoprim (BDP) 400 mg loading dose followed by 200 mg once a day
Number of subjects: 519
Study 8195847 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin (AMX) 750 mg t.i.d
Number of subjects: 519
Study 29759925 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 500mg orally every eight hours for seven days
Number of subjects: 96
Study 29759925 — intervention group
Group type: COMPARATOR
Intervention: Observation group
Number of subjects: 96
Study 27075370 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid palatal expansion with a hyrax-type expander, activated twice a day for 15 days to obtain 7.5 mm of palatal expansion, left in situ for six months.
Number of subjects: 20
Study 27075370 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment, only observation).
Number of subjects: 20
Study 24993326 — intervention group
Group type: EXPERIMENTAL
Intervention: Artiflex phakic IOL (Ophtec BV) - Group A
Number of subjects: 46
Study 24993326 — intervention group
Group type: COMPARATOR
Intervention: PRK‐MMC - Group B
Number of subjects: 46
Study 21808075 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingual two-dimensional (2D) technique, 25 patients (19 females and 6 males)
Number of subjects: 50
Study 21808075 — intervention group
Group type: COMPARATOR
Intervention: Labial straightwire (SW) technique, 25 patients (20 females and 5 males)
Number of subjects: 50
Study 20456813 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy diet+PS (2 g/d of PS)
Number of subjects: 84
Study 20456813 — intervention group
Group type: EXPERIMENTAL
Intervention: Free diet+PS (2 g/d of PS)
Number of subjects: 84
Study 20456813 — intervention group
Group type: COMPARATOR
Intervention: Healthy diet
Number of subjects: 84
Study 20456813 — intervention group
Group type: EXPERIMENTAL
Intervention: Free diet+PS
Number of subjects: 84
Study 20456813 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy diet+PS
Number of subjects: 84
Study 18556683 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg)
Number of subjects: 21
Study 18556683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 18556683 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Infliximab and Placebo) after surgery
Number of subjects: 21
Study 16020941 — intervention group
Group type: EXPERIMENTAL
Intervention: Persons with dementia
Number of subjects: 121
Study 16020941 — intervention group
Group type: COMPARATOR
Intervention: Persons without dementia
Number of subjects: 121
Study 12449166 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol Turbuhaler 18 microg b.i.d.
Number of subjects: 183
Study 12449166 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 80 microg t.i.d.
Number of subjects: 183
Study 12449166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study 10599658 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 500-mg tablet of levofloxacin (group 1, 22 patients)
Number of subjects: 45
Study 10599658 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 500-mg tablets of levofloxacin (group 2, 23 patients)
Number of subjects: 45
Study 7794081 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation therapy (Fluorouracil, cisplatin, and 4500 cGy over 5 weeks)
Number of subjects: 43
Study 7794081 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation therapy
Number of subjects: 43
Study 7794081 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 43
Study 2020773 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen combined with nitroimidazoles as a radiation sensitiser
Number of subjects: 0
Study 2020773 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Number of subjects: 0
Study 2020773 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen combined with induced anaemia
Number of subjects: 0
Study 7075651 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol 320 mg once daily
Number of subjects: 12
Study 7075651 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol 160 mg twice daily
Number of subjects: 12
Study 7075651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31809224 — intervention group
Group type: EXPERIMENTAL
Intervention: DRL_RI
Number of subjects: 151
Study 31809224 — intervention group
Group type: COMPARATOR
Intervention: RMP
Number of subjects: 151
Study 29941380 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of ibuprofen
Number of subjects: 20
Study 29941380 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of ibuprofen
Number of subjects: 20
Study 29941380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 27855099 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention provided by Accredited Social Health Activists (ASHAs) comprising group-based education and support for self-management of blood pressure.
Number of subjects: 14500
Study 27855099 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 14500
Study 24104511 — intervention group
Group type: EXPERIMENTAL
Intervention: Year-long behavioral intervention
Number of subjects: 192
Study 22094472 — intervention group
Group type: EXPERIMENTAL
Intervention: Brisk walking for 2 hours at ∼50% maximal oxygen uptake
Number of subjects: 12
Study 19180214 — intervention group
Group type: EXPERIMENTAL
Intervention: Agility training group (trained 4 times per week for 6 weeks)
Number of subjects: 30
Study 19180214 — intervention group
Group type: COMPARATOR
Intervention: Control group (did not participate in agility training)
Number of subjects: 30
Study 19180214 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 30
Study 17524266 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV) 10 mg once daily for 12 weeks
Number of subjects: 83
Study 17524266 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV) for 52 weeks (Group B)
Number of subjects: 83
Study 17524266 — intervention group
Group type: COMPARATOR
Intervention: Adefovir dipivoxil (ADV) for 40 weeks followed by placebo for 12 weeks (Group C)
Number of subjects: 83
Study 17524266 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV) for 52 weeks (Group A and B)
Number of subjects: 83
Study 17524266 — intervention group
Group type: COMPARATOR
Intervention: Adefovir dipivoxil (ADV) for 52 weeks (Group C)
Number of subjects: 83
Study 17524266 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV) for 156 weeks
Number of subjects: 83
Study 15174920 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular AAA repair
Number of subjects: 76
Study 15174920 — intervention group
Group type: COMPARATOR
Intervention: Open AAA repair
Number of subjects: 76
Study 12241832 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg once daily)
Number of subjects: 5477
Study 12241832 — intervention group
Group type: COMPARATOR
Intervention: Captopril (50 mg three times daily)
Number of subjects: 5477
Study 12241832 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 5477
Study 12241832 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 5477
Study 9767241 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreserved cultured allogeneic keratinocyte sheets and compression bandages
Number of subjects: 27
Study 9767241 — intervention group
Group type: COMPARATOR
Intervention: Compression only
Number of subjects: 27
Study 8205603 — intervention group
Group type: EXPERIMENTAL
Intervention: TCV-116 (2.5 mg and greater)
Number of subjects: 36
Study 8205603 — intervention group
Group type: EXPERIMENTAL
Intervention: TCV-116 (repeated administration, once-daily for 8 days)
Number of subjects: 36
Study 8205603 — intervention group
Group type: EXPERIMENTAL
Intervention: TCV-116 (single doses)
Number of subjects: 36
Study 8205603 — intervention group
Group type: EXPERIMENTAL
Intervention: TCV-116 (first 24 hours post-administration)
Number of subjects: 36
Study 8205603 — intervention group
Group type: EXPERIMENTAL
Intervention: TCV-116 (repeated administration)
Number of subjects: 36
Study 8205603 — intervention group
Group type: EXPERIMENTAL
Intervention: TCV-116
Number of subjects: 36
Study 2913958 — intervention group
Group type: EXPERIMENTAL
Intervention: Tioconazole
Number of subjects: 2
Study 2913958 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 2
Study 2913958 — intervention group
Group type: COMPARATOR
Intervention: Miconazole nitrate
Number of subjects: 2
Study 30561840 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (GABA B receptor agonist)
Number of subjects: 24
Study 31026250 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron (PG)
Number of subjects: 200
Study 31026250 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron (OG)
Number of subjects: 200
Study 29040481 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-suction neck drain
Number of subjects: 40
Study 29040481 — intervention group
Group type: COMPARATOR
Intervention: No neck drain (control)
Number of subjects: 40